eccrine porocarcinoma : Response to docetaxel ( Taxotere ) chemotherapy "
eccrine porocarcinoma : Response to docetaxel ( Taxotere ) chemotherapy "
复制标题
小汗腺汗孔癌：对多西紫杉醇（泰索帝）化疗的反应“
DOI：
--
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
R. Rubens
中科院分区：
文献类型：
--
作者：
T. A. Plunkett;A. Hanby;D. Miles;R. Rubens
背景：汗腺汗腺癌是一种罕见的表皮内汗腺导管肿瘤。患者和方法：描述一例45岁女性肾移植患者的小汗腺孔癌病例，并复习相关文献。结果：1原发肿瘤高度多形性。在一些地方，大小细胞融合在一起，前一种成分以类似于乳房佩吉特氏病的方式渗入表皮。大多数肿瘤为高级别；采用改良的Bloom和Richardson分级系统，肿瘤分级为3级。初次手术治疗后9个月发生转移。转移性小汗腺癌对表阿霉素耐药，但对多西紫杉醇化疗有效。结论：没有数据支持在小汗腺孔癌的治疗中使用辅助治疗。使用改良的Bloom和Richardson分级系统可以确定复发风险高的病例，在这些病例中可以考虑辅助治疗。转移性小汗腺癌已被证明对多种化疗药物耐药。我们首次报告了多西紫杉醇在这种疾病的治疗中的应用。该治疗耐受性良好，并产生了显著的症状和放射反应。在这种罕见肿瘤的未来病例中，应该考虑多西紫杉醇的治疗！
' Backgrouadl Eccrine porocarcinoma is an uncommon neoplasm of the intra-epidermal sweat gland duct. Patients and methods: A case of eccrine porocarcinoma in a female renal transplant patient aged 45 years is described with a review of pertinent literature. ^Results:^The primary tumour was highly pleomorphic. In places large and small cells merged and focally the former component infiltrated the epidermis in a manner akin to Paget's disease of the breast. The majority of the tumour was high grade; using the modified Bloom and Richardson grading system, usually applied to mammary ductal carcinomas, the tumour graded as 3. Metastatic disease developed nine months following primary surgical treatment. The metastatic eccrine porocarcinoma was resistant to epirubicin but responded to docetaxel chemotherapy. Conclusions: There are no data to support the use of adjuvant therapy in the management of eccrine porocarcinoma. The use of the modified Bloom and Richardson grading system may define cases at high risk of relapse in which adjuvant therapy might be considered. Metastatic eccrine porocarcinoma has proven resistant to many chemotherapeulic agents. We report the first use of docetaxel in the management of this disease. The treatment was well tolerated and resulted in marked symptomatic and radiological responses. Treatment with docetaxel should be considered in future cases of this rare tumour!